← Back to Search

Monoclonal Antibodies

Patients with Stage IIIb/IV Non-Small Cell Lung Cancer for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Priya Kumar, MD
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment through 2 years
Awards & highlights

Study Summary

The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment through 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment through 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Progression
Secondary outcome measures
Best Overall Response by Cycle
Duration of Response
Overall Survival Time
+1 more

Side effects data

From 2010 Phase 2 trial • 38 Patients • NCT00400803
71%
Gastrointestinal
63%
Constitutional symptoms
61%
Pain
58%
Pulmonary/upper respiratory
32%
Neurology
32%
Cardiac general
21%
Dermatology/skin
21%
Infection
21%
Ocular/visual
18%
Metabolic/laboratory
16%
Blood/bone marrow
16%
Lymphatics
13%
Musculoskeletal/soft tissue
11%
Renal/genitourinary
11%
Pulmonary embolism
8%
Allergy/immunology
8%
Auditory/Ear
5%
Diarrhea
5%
Hemorrhage/bleeding
5%
Endocrine
5%
Hypertension
5%
Syndromes
5%
Headache
5%
Dizziness
3%
Proteinuria
3%
Vomiting
3%
Fatigue
3%
Back Pain
3%
Bilateral hearing loss
3%
Neutropenia
3%
Joint Pain
3%
Ataxia
3%
Pain, musculoskeletal
3%
Constipation
3%
Syncope
3%
Thrombocytopenia (bruising)
3%
Sensory neuropathy
3%
Hemorrhage, pulmonary
3%
Fever
3%
Neck Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Intent To Treat - Lung Cancer Patients

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with Stage IIIb/IV Non-Small Cell Lung CancerExperimental Treatment1 Intervention
Patients treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gemcitabine
FDA approved

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
272 Previous Clinical Trials
14,615 Total Patients Enrolled
Genentech, Inc.Industry Sponsor
1,541 Previous Clinical Trials
568,015 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,623 Previous Clinical Trials
3,216,957 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
2007. "Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00400803.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top